Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
-$0.06 today
- Market cap
- $59.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
Volume 0.19M
Average 0.43M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Fortress Biotech, Inc.
NASDAQ:FBIO
Intrinsic Alpha fair value
Locked
Current Price
$1.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -5.8% | +40.4% (2yr)1 analysts |
| Net Income | N/A | N/A | N/A | +89.6% (2yr)1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -5.8% over three years. Forward estimates point to Net Income at +89.6% (2yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Relmada Therapeutics, Inc. NASDAQ:RLMD | $449.08M | $4.21 | Not rated | -9.6 | -28.01% |
Immunic, Inc. NASDAQ:IMUX | $102.61M | $7.52 | Not rated | -4.1 | +7.41% |
Vaxart, Inc. NASDAQ:VXRT | $90.17M | $0.37 | Undervalued | 3.6 | +40.58% |
Nutriband Inc. NASDAQ:NTRB | $74.15M | $6.10 | Not rated | -1.8 | -0.79% |
PMV Pharmaceuticals, Inc. NASDAQ:PMVP | $67.73M | $1.27 | Not rated | -0.8 | +0.00% |
Adagene Inc. NASDAQ:ADAG | $64.38M | $1.71 | Not rated | -7.9 | +13.56% |
XBiotech Inc. NASDAQ:XBIT | $59.76M | $1.96 | Not rated | -1.8 | -24.32% |
Gain Therapeutics, Inc. NASDAQ:GANX | $44.36M | $1.04 | Not rated | -3.6 | -58.60% |
TScan Therapeutics, Inc. NASDAQ:TCRX | $10.20M | $0.16 | Not rated | -1.0 | -16.29% |
Continue the stock analysis
Jump to another research area for this company.